A Phase I trial evaluating mucosal administration of a candidate TB vaccine, MVA85A, as a way to induce potent local cellular immune responses and avoid anti-vector immunity
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2019
Price : $35 *
At a glance
- Drugs MVA 85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Acronyms TB035
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 27 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 04 Sep 2015 Accrual to date is 102% according to United Kingdom Clinical Research Network record.